Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway

Cancer Cell International

Weiping Xie¹  Hong Wang¹  Hui Kong¹  Xiaoning Zeng¹  Wenqiu Ding¹  Xiaolin Li²  Huae Xu¹ 

[1] Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, 300# Guangzhou Road, Nanjing 210029, People’s Republic of China;Department of Geriatric Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China

关键词: Apoptosis;    Akt;    ROS;    Lung cancer;    Deguelin;   

Others  :  1138464
DOI  :  10.1186/s12935-015-0166-4

 received in 2014-12-04, accepted in 2015-01-20,  发布年份 2015

【 摘 要 】

Background

Duguelin is a rotenoid extracted from plants and has potent antitumor effects in vitro and in vivo. However, the mechanism underlying the antitumor effect remains unclear. Our preliminary study showed that Deguelin is effective to stimulate the generation of Reactive Oxygen Species (ROS). In the current study, we evaluated the in vitro cytotoxicity of Deguelin against lung cancer cells and studied whether a ROS scavenger, N-acetyl-cysteine (NAC), can reverse the inhibitory effect of Deguelin.

Results

We showed that the dose-dependent apoptotic inducing effect of Deguelin could be partially reversed by the co-administration of NAC. Moreover, Deguelin reduced the phosphorylation of Akt protein and induced the apoptotic protein Caspase-3 in a dose-dependent manner. Co-treatment with NAC partially attenuated this effect and rescued some cells from apoptosis.

Conclusion

Deguelin induces the apoptosis of cancer cells through a ROS driven Akt pathway, which could translate into a promising therapeutic for lung cancer.

【 授权许可】

   
2015 Xu et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
• [2]Livshits Z, Rao RB, Smith SW: An approach to chemotherapy-associated toxicity. Emerg Med Clin North Am 2014, 32:167-203.
• [3]Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, et al.: Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One 2013, 8:e65113.
• [4]Kang HW, Kim JM, Cha MY, Jung HC, Song IS, Kim JS: Deguelin, an Akt inhibitor, down-regulates NF-kappaB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice. Dig Dis Sci 2012, 57:2873-2882.
• [5]Ji BC, Yu CC, Yang ST, Hsia TC, Yang JS, Lai KC, et al.: Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells. Oncol Rep 2012, 27:959-964.
• [6]Lee H, Lee JH, Jung KH, Hong SS: Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer. Oncol Rep 2010, 24:957-963.
• [7]Murillo G, Salti GI, Kosmeder JW 2nd, Pezzuto JM, Mehta RG: Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur J Cancer 2002, 38:2446-2454.
• [8]Peng XH, Karna P, O’Regan RM, Liu X, Naithani R, Moriarty RM, et al.: Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol 2007, 71:101-111.
• [9]Chu ZH, Liang XH, Zhou XL, Huang RF, Zhan Q, Jiang JW: [Effects of deguelin on proliferation and apoptosis of MCF-7 breast cancer cells by phosphatidylinositol 3-kinase/Akt signaling pathway]. Zhong Xi Yi Jie He Xue Bao 2011, 9:533-538.
• [10]Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK, et al.: Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 2007, 67:11630-11639.
• [11]Zhou L, Luan H, Liu Q, Jiang T, Liang H, Dong X, et al.: Activation of PI3K/Akt and ERK signaling pathways antagonized sinomenine-induced lung cancer cell apoptosis. Mol Med Rep 2012, 5:1256-1260.
• [12]Puglisi M, Thavasu P, Stewart A, de Bono JS, O’Brien ME, Popat S, et al.: AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines. Lung Cancer 2014, 85:141-146.
• [13]Gunda V, Bucur O, Varnau J, Vanden Borre P, Bernasconi MJ, Khosravi-Far R, et al.: Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis 2014, 5:e1104.
• [14]Zhang C, Cao S, Toole BP, Xu Y: Cancer may be a pathway to cell survival under persistent hypoxia and elevated ROS: a model for solid-cancer initiation and early development. Int J Cancer 2014. doi: 10.1002/ijc.28975.
• [15]El Sayed SM, Mahmoud AA, El Sawy SA, Abdelaal EA, Fouad AM, Yousif RS, et al.: Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect). Med Hypotheses 2013, 81:866-870.
• [16]Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004, 7:97-110.
• [17]Benhar M, Engelberg D, Levitzki A: ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002, 3:420-425.
• [18]Li X, Lu X, Xu H, Zhu Z, Yin H, Qian X, et al.: Paclitaxel/tetrandrine coloaded nanoparticles effectively promote the apoptosis of gastric cancer cells based on “oxidation therapy”. Mol Pharm 2012, 9:222-229.
• [19]Li X, Xu H, Dai X, Zhu Z, Liu B, Lu X: Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer. Int J Nanomedicine 2012, 7:5183-5190.
• [20]Chetram MA, Bethea DA, Odero-Marah VA, Don-Salu-Hewage AS, Jones KJ, Hinton CV: ROS-mediated activation of AKT induces apoptosis via pVHL in prostate cancer cells. Mol Cell Biochem 2013, 376:63-71.
• [21]Hussain AR, Uddin S, Bu R, Khan OS, Ahmed SO, Ahmed M, et al.: Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PLoS One 2011, 6:e24703.
• [22]Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, Sellers R, et al.: ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3 (−/−) mice. EMBO J 2010, 29:4118-4131.
• [23]Esmaeili MA, Farimani MM, Kiaei M: Anticancer effect of calycopterin via PI3K/Akt and MAPK signaling pathways, ROS-mediated pathway and mitochondrial dysfunction in hepatoblastoma cancer (HepG2) cells. Mol Cell Biochem 2014, 397:17-31.
• [24]Palanivel K, Kanimozhi V, Kadalmani B, Akbarsha MA: Verrucarin a induces apoptosis through ROS-mediated EGFR/MAPK/Akt signaling pathways in MDA-MB-231 breast cancer cells. J Cell Biochem 2014, 115:2022-2032.
• [25]Cao J, Xu D, Wang D, Wu R, Zhang L, Zhu H, et al.: ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic Biol Med 2009, 47:536-547.
• [26]Dolado I, Nebreda AR: AKT and oxidative stress team up to kill cancer cells. Cancer Cell 2008, 14:427-429.
• [27]Dall'Acqua S, Linardi MA, Bortolozzi R, Clauser M, Marzocchini S, Maggi F, Nicoletti M, Innocenti G, Basso G, Viola G: Natural daucane esters induces apoptosis in leukaemic cells through ROS production. Phytochemistry 2014, 108:147-156.
• [28]Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS: Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 2005, 65:8455-8460.
• [29]Yang JC, Lu MC, Lee CL, Chen GY, Lin YY, Chang FR, et al.: Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K. Free Radic Biol Med 2011, 51:641-657.
• [30]Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, et al.: Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011, 475:231-234.
• [31]Gibson KR, Neilson IL, Barrett F, Winterburn TJ, Sharma S, MacRury SM, et al.: Evaluation of the antioxidant properties of N-acetylcysteine in human platelets: prerequisite for bioconversion to glutathione for antioxidant and antiplatelet activity. J Cardiovasc Pharmacol 2009, 54:319-326.
• [32]Zhu C, Hu W, Wu H, Hu X: No evident dose–response relationship between cellular ROS level and its cytotoxicity–a paradoxical issue in ROS-based cancer therapy. Sci Rep 2014, 4:5029.
• [33]Zhang H, Li X, Ding J, Xu H, Dai X, Hou Z, et al.: Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). Int J Pharm 2013, 441:261-268.
• [34]Shao J, Zheng D, Jiang Z, Xu H, Hu Y, Li X, et al.: Curcumin delivery by methoxy polyethylene glycol-poly (caprolactone) nanoparticles inhibits the growth of C6 glioma cells. Acta Biochim Biophys Sin (Shanghai) 2011, 43:267-274.
• [35]Li X, Zhen D, Lu X, Xu H, Shao Y, Xue Q, et al.: Enhanced cytotoxicity and activation of ROS-dependent c-Jun NH2-terminal kinase and caspase-3 by low doses of tetrandrine-loaded nanoparticles in Lovo cells–a possible Trojan strategy against cancer. Eur J Pharm Biopharm 2010, 75:334-340.
• [36]Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, et al.: Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 2007, 99:949-961.
• [37]Yang YL, Ji C, Bi ZG, Lu CC, Wang R, Gu B, et al.: Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. PLoS One 2013, 8:e54736.
• [38]Abraham J: PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies? Expert Rev Anticancer Ther 2014, 151:1-18.
• [39]Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R: Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. Lung Cancer Manag 2014, 3:67-75.
• [40]Xing CG, Zhu BS, Fan XQ, Liu HH, Hou X, Zhao K, et al.: Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice. World J Gastroenterol 2009, 15:5044-5052.
• [41]Yun J, Lv YG, Yao Q, Wang L, Li YP, Yi J: Wortmannin inhibits proliferation and induces apoptosis of MCF-7 breast cancer cells. Eur J Gynaecol Oncol 2012, 33:367-369.
• [42]Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, Cappellini A, et al.: Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol 2005, 129:677-686.
• [43]McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, et al.: Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Adv Enzyme Regul 2008, 48:113-135.
• [44]Chen X, Wang H, Ou-Yang XN, Xie FW, Wu JJ: Research on drug resistance mechanism of trastuzumab caused by activation of the PI3K/Akt signaling pathway. Contemp Oncol (Pozn) 2013, 17:363-369.
• [45]Jiang S, Zhu W, Wu J, Li C, Zhang X, Li Y, et al.: alpha-lipoic acid protected cardiomyoblasts from the injury induced by sodium nitroprusside through ROS-mediated Akt/Gsk-3beta activation. Toxicol In Vitro 2014, 28:1461-1473.
• [46]Yuan L, Wei S, Wang J, Liu X: Isoorientin induces apoptosis and autophagy simultaneously by reactive oxygen species (ROS)-related p53, PI3K/Akt, JNK, and p38 signaling pathways in HepG2 cancer cells. J Agric Food Chem 2014, 62:5390-5400.
• [47]Xu H, Hou Z, Zhang H, Kong H, Li X, Wang H, et al.: An efficient Trojan delivery of tetrandrine by poly (N-vinylpyrrolidone)-block-poly (epsilon-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion. Int J Nanomedicine 2014, 9:231-242.